The Practical Evidence of Antidiabetic Combination Therapy in Korea
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 216 participants.
Also called NCT02231021
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 216 participants
- Sponsor
- Registry
-
NCT02231021
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT02231021. Randomized; quadruple masking; primary purpose treatment. Start 2014-09 (actual); primary completion 2018-10-22 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Practical Evidence of Antidiabetic Combination Therapy in Korea
- Acronym
- PEAK
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- alogliptin
- Intervention (Drug)
- Pioglitazone
- Intervention (Drug)
- alogliptin + pioglitazone
- Lead sponsor
- Kun-Ho Yoon
- Collaborator
- Takeda
Record details
- Record id
cardio:ct-nct02231021- Content hash
eb59292184eb84a5d804185b470a745e94110a638a46cd4d866a96c906428994